{"ruRx4o0AAAAJ": [["Kenneth R Chapman", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Darcy D Marciniuk", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["CanCOLD Collaborative Research Group and the Canadian Respiratory Research Network", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Wan C Tan", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Fran\u00e7ois Maltais", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Seyed\u2010Mohammad\u2010Yousof Mostafavi\u2010Pour\u2010Manshadi", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Miriam Barrecheguren", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Pei Z Li", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Andrea Benedetti", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Jean Bourbeau", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["J Mark Fitzgerald", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Don D Sin", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Shawn D Aaron", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Brandie Walker", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Lancelot Pinto", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Paul Hernandez", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Denis E O'Donnell", 2020, "Identification and definition of asthma\u2013COPD overlap: The CanCOLD study"], ["Xavier Mu\u00f1oz", 2020, "Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles"], ["Steven Smith", 2020, "Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles"], ["Frank Albers", 2020, "Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles"], ["Bradley Chipps", 2020, "Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles"], ["Jay Azmi", 2020, "Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles"], ["Robert Price", 2020, "Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles"], ["Dmitri Galkin", 2020, "Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles"], ["Kenneth Chapman", 2020, "Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles"], ["Miguel Bergna", 2020, "Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles"], ["Mark Liu", 2020, "Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles"], ["Gilles Devouassoux", 2020, "Therapeutic Switch from Omalizumab to Mepolizumab in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles"], ["Erika Penz", 2019, "Targeted management of severe asthma: Developing a Canadian approach"], ["J Mark FitzGerald", 2019, "Targeted management of severe asthma: Developing a Canadian approach"], ["Alfred Yamamoto", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Richard F Rideout", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Arthur F Gelb", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Christine Fraser", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Jay A Nadel", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Mark Schein", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["James C Hogg", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Eric F Glassy", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Roxanna M Moridzadeh", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Eric K Verbeken", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Diem NT Tran", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Marc Decramer", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Noe Zamel", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Amanda Post", 2019, "Normal Routine Spirometry Can Mask Clinical and Physiologic Detection of COPD and Emphysema in Symptomatic Smokers"], ["Guohai Zhou", 2019, "The effects of marijuana smoking on lung function in older people"], ["Denis O'Donnell", 2019, "The effects of marijuana smoking on lung function in older people"], ["Teresa To", 2019, "The effects of marijuana smoking on lung function in older people"], ["Liyun Zheng", 2019, "The effects of marijuana smoking on lung function in older people"], ["Brandie L Walker", 2019, "The effects of marijuana smoking on lung function in older people"], ["Trevor Yau", 2019, "The effects of marijuana smoking on lung function in older people"], ["Alex Stenzler", 2019, "System and method for controlling the harshness of nicotine-based dry powder formulations"], ["Steven Ellis", 2019, "System and method for controlling the harshness of nicotine-based dry powder formulations"], ["Steve Han", 2019, "System and method for controlling the harshness of nicotine-based dry powder formulations"], ["Arthur Slutsky", 2019, "System and method for controlling the harshness of nicotine-based dry powder formulations"], ["Robert Bals", 2019, "Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD"], ["Nicholas S Hopkinson", 2019, "Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD"], ["Eeva Piitulainen", 2019, "Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD"], ["Jan Stolk", 2019, "Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD"], ["William MacNee", 2019, "Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD"], ["Robert A Stockley", 2019, "Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD"], ["Pablo Fernandez", 2019, "Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD"], ["Gerry McElvaney", 2019, "Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD"], ["Niels Seersholm", 2019, "Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD"], ["Naveh Tov", 2019, "Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD"], ["Claus F Vogelmeier", 2019, "Efficacy and safety of inhaled \u03b11-antitrypsin in patients with severe \u03b11-antitrypsin deficiency and frequent exacerbations of COPD"], ["Darcy Marciniuk", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["John Kimoff", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Robert Cowie", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Milo Puhan", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Ron Clemens", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Matthew McNeil", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Catherine Peng", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Jonathon Samet", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Tasha Nadirshaw", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Jonathon Leipsic", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Atul Malhotra", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Jacinthe Baril", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Christine Lo", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Bin Zhao", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Sarah Cheng", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Marta Kaminska", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Nadeen Audisho", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Yvan Fortier", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Gay Pratt", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Matthew Shorofsky", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Ann Cowie", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Canadian Respiratory Research Network", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Rachel Jen", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Amanda Wong", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Sheena Tam", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["DD Sin", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Patricia McClean", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Jean-Francois Duquette", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Denis Jensen", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Harvey Coxson", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Najib Ayas", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Pei-Zhi Li", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Kathy Vandemheen", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Curtis Dumonceaux", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Scott Fulton", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Don Sin", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Mohsen Sadatsafavi", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Cameron Hague", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["F Maltais", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Nathalie Scott-Hsiung", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Laura Labonte", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Nancy Haynes", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Selva Bayat", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Denis E O\u2019Donnell", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Zoe Alavi", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Palmina Mancino", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Nancy Ferguson", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Carole Baglole", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Carole Jabet", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Licong Li", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Kate Whelan", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Janet Baran", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["David Latreille", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Jeremy Road", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Joe Comeau", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Qutayba Hamid", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Miranda Kirby", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Adrian Png", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Cynthia Brouillard", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["DD Marciniuk", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Amanda Bergeron", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Andrea Gershon", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Shawn Aaron", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Cindy Fung", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Junior Chuang", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["DE O'Donnell", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Lisette Machado", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Francois Maltais", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Kristen Osterling", 2019, "Impaired sleep quality in COPD is associated with exacerbations: the cancold cohort study"], ["Katherine A Siminovitch", 2019, "Variation at DENND1B and Asthma on the Island of Tristan da Cunha"], ["Nicholas G Martin", 2019, "Variation at DENND1B and Asthma on the Island of Tristan da Cunha"], ["Ricardo Zamel", 2019, "Variation at DENND1B and Asthma on the Island of Tristan da Cunha"], ["David L Duffy", 2019, "Variation at DENND1B and Asthma on the Island of Tristan da Cunha"], ["Benjamin Scirica", 2019, "ACLIDINIUM BROMIDE TREATMENT STRATIFIED BY EXACERBATION HISTORY: EFFECTS ON EXACERBATIONS AND MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH COPD AND HIGH CARDIOVASCULAR RISK \u2026"], ["Robert Wise", 2019, "ACLIDINIUM BROMIDE TREATMENT STRATIFIED BY EXACERBATION HISTORY: EFFECTS ON EXACERBATIONS AND MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH COPD AND HIGH CARDIOVASCULAR RISK \u2026"], ["Dan Lythgoe", 2019, "ACLIDINIUM BROMIDE TREATMENT STRATIFIED BY EXACERBATION HISTORY: EFFECTS ON EXACERBATIONS AND MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH COPD AND HIGH CARDIOVASCULAR RISK \u2026"], ["Sami Daoud", 2019, "ACLIDINIUM BROMIDE TREATMENT STRATIFIED BY EXACERBATION HISTORY: EFFECTS ON EXACERBATIONS AND MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH COPD AND HIGH CARDIOVASCULAR RISK \u2026"], ["Esther Garcia Gil", 2019, "ACLIDINIUM BROMIDE TREATMENT STRATIFIED BY EXACERBATION HISTORY: EFFECTS ON EXACERBATIONS AND MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH COPD AND HIGH CARDIOVASCULAR RISK \u2026"], ["Jens M Hohlfeld", 2019, "Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma"], ["Henrik Watz", 2019, "Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma"], ["Jutta Beier", 2019, "Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma"], ["Zuzana Diamant", 2019, "Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma"], ["Hanns-Christian Tillmann10", 2019, "Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma"], ["Ieuan Jones", 2019, "Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma"], ["Ruobing Li", 2019, "Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma"], ["Pascale Pinot10", 2019, "Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma"], ["Dave Singh", 2019, "Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma"], ["Veronika Scholz", 2019, "Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma"], ["Hanns-Christian Tillmann", 2019, "Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma"], ["Pascale Pinot", 2019, "Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma"], ["Arnab Sarkar", 2019, "Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma"], ["Richard Follows", 2019, "Self-administration of mepolizumab liquid using a single-use prefilled autoinjector"], ["Eric Bradford", 2019, "Self-administration of mepolizumab liquid using a single-use prefilled autoinjector"], ["Isabelle Pouliquen", 2019, "Self-administration of mepolizumab liquid using a single-use prefilled autoinjector"], ["Jane H Bentley", 2019, "Self-administration of mepolizumab liquid using a single-use prefilled autoinjector"], ["Ian D Pavord", 2019, "Self-administration of mepolizumab liquid using a single-use prefilled autoinjector"], ["David Bernstein", 2019, "Self-administration of mepolizumab liquid using a single-use prefilled autoinjector"], ["Job FM van Boven", 2019, "The Hidden Story of Nonadherence with Asthma Therapy: For a Few Dollars More?"], ["Robert G Price", 2019, "The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma"], ["Frank C Albers", 2019, "The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma"], ["Dalal Mouneimne", 2019, "The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma"], ["Dmitry Galkin", 2019, "The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma"], ["Mark C Liu", 2019, "The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma"], ["Sin\u00e9ad Lambe", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Thomas Kabir", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Andrew Goodsell", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["David M Clark", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Eileen O'regan", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Humma Andleeb", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Dan Robotham", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["John R Geddes", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Tillie L Cryer", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Daniel Freeman", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Jos\u00e9 Leal", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Robert Dudley", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Felicity Waite", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Kate Chapman", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Jen Martin", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Aitor Rovira", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Aislinn Bergin", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Chris Hollis", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Laina Rosebrock", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Susan Brown", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Michael Craven", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Anthony Morrison", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["Ly-Mee Yu", 2019, "Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)"], ["KR Chapman", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Responder analysis"], ["M Bergna", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Responder analysis"], ["MC Liu", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Responder analysis"], ["D Galkin", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Responder analysis"], ["X Munoz", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Responder analysis"], ["E Mavropoulou", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Responder analysis"], ["FC Albers", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Responder analysis"], ["B Chipps", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Responder analysis"], ["G Devouassoux", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Responder analysis"], ["BE Chipps", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Treatment effect by nasal polyps, aspirin/NSAID intolerance, and GERD"], ["RG Price", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Treatment effect by nasal polyps, aspirin/NSAID intolerance, and GERD"], ["MA Bergna", 2019, "Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Treatment effect by nasal polyps, aspirin/NSAID intolerance, and GERD"], ["David Buchanan", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Laura Burgess", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Aryelly Rodriguez", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jessica Redgrave", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Martin S Dennis", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Gillian Mead", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["John Bamford", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jennifer Adil-Smith", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Sally Marshall", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Joseph Devine", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Kheng Xiong Ng", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Devesh Sinha", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Harbens Bhakri", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["David Minks", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Clare Doyle", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Isam Salih", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jordi Morell", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Rowilson Jarapa", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Richard O'Brien", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Colin Baigent", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Stephanie Lee", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jane Armitage", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Allan MacRaild", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Rangah Niranchanan", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["David J Werring", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["David Ngo", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["David P Minks", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Christine Kamara", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Ruth Fraser", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Thayalini Loganathan", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Pauline Bayliss", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Mushiya Mpelembue", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Martin Punter", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Rajalakshmi Orath Prabakaran", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Rajaram Bathula", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Seona Burgess", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Georgina Ayres", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Gabriel Rinkel", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Olesia Balitska", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Yogish Joshi", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Lynn Dinsmore", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["David Perry", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Dawn Tomlin", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Johanna Carrie", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Sindhu Rashmi", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Angela Chamberlain", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Kathleen Horan", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Debs Kelly", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Edith Wood", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Luke Barron", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Ruth Paulton", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Gordon Lowe", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Kathryn Birchall", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jean Buxton", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Swapna Kunhunny", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Andrea Hall", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Ali Ali", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Aileen McGrath", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jonathan Emberson", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["David Cohen", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Andrea Ingham", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Shannon Amoils", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Arshad Majis", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Anette David", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Silvie Davies", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Kelechi Njoku", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Richard Parker", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Joanne Garfield-Smith", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Faith Kibutu", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Thomas Gattringer", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Mary Johnes", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Neil Hunter", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Pauline Fitzell", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Ruwan Parakramawansha", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Dipayan Mitra", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jo Howe", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["William N Whiteley", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Malcolm Macleod", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Radim Licenik", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Nabeela Nisar", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Aidan Hutchison", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Mark A Rodrigues", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Kelly Marie Shaw", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Anwer Siddiqui", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Gordon D Murray", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Helen Bearne", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Shyam Kelavkar", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Lucy Coward", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Susan Szabo", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Pat Taylor", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Afaq Saulat", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Anne Oshodi", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jack Perry", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Javier Rojas", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Johann C du Plessis", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Mudhar Abbdul-saheb", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Joanna M Wardlaw", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Sharon Tysoe", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Louise Harrison", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Ralf Lindert", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Connor McGill", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Frank Sullivan", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["David E Newby", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Emmanuelle Owoyele", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Fenglin Guo", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Philip Poku", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Fergus Doubal", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Pauli Walker", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Ilse Burger", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jacqueline Stephen", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Aberami Chandrakumar", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Tracy Marsden", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Victoria O'Loughlin", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Kathy Stocks", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Gordon Blair", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Robert Ballantine", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Johannes du Plessis", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Daniel Lasserson", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Christopher Matthews", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Tatjana Roganova", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Cathie LM Sudlow", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Carol Williams", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Peter AG Sandercock", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Rosemary Anderson", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Amber Siddiqui", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Eleni Sakka", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Katrina McCormick", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Biju Bhaskaran", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Rustam Al-Shahi Salman", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Philip M White", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jane Perez", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Karen Innes", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Emma Richards", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jonathan Drever", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Catrin Blank", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Jeb Palmer", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Mmua Ngwako", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Allan Walker", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Ahmad Maatouk", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Adrian Parry-Jones", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Ann Deary", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Katy Dakin", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Nikola Sprigg", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Varthi Sukdeo", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Christian Hansen", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Christine Lerpiniere", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Kirsty Harkness", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Zin Naing", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Paul Guyler", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Priya Bhatnagar", 2019, "Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART \u2026"], ["Donald D Sin", 2017, "Undiagnosed Chronic Obstructive Pulmonary Disease Leads To A Significant Symptom Burden, With Important Differences Between Men And Women"], ["Joshua Wald", 2017, "Undiagnosed Chronic Obstructive Pulmonary Disease Leads To A Significant Symptom Burden, With Important Differences Between Men And Women"], ["Oliver Vit", 2017, "The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of The Rapid/rapid Extension Trial"], ["David Parr", 2017, "The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of The Rapid/rapid Extension Trial"], ["Jonathan M Edelman", 2017, "The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of The Rapid/rapid Extension Trial"], ["Berend Stoel", 2017, "The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of The Rapid/rapid Extension Trial"], ["Noel G McElvaney", 2017, "The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of The Rapid/rapid Extension Trial"], ["Jonathan Burdon", 2017, "The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of The Rapid/rapid Extension Trial"], ["Marion Wencker", 2017, "The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of The Rapid/rapid Extension Trial"], ["Darren Reed", 2017, "The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of The Rapid/rapid Extension Trial"], ["Michael Fries", 2017, "The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of The Rapid/rapid Extension Trial"], ["Chau Thach", 2017, "Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus Salmeterol/fluticasone: Results From The Flame Study"], ["Robert Fogel", 2017, "Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus Salmeterol/fluticasone: Results From The Flame Study"], ["Anthony Yadao", 2017, "Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus Salmeterol/fluticasone: Results From The Flame Study"], ["Francesco Patalano", 2017, "Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus Salmeterol/fluticasone: Results From The Flame Study"], ["Tim Ayers", 2017, "Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus Salmeterol/fluticasone: Results From The Flame Study"], ["Angel Fowler Taylor", 2017, "Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus Salmeterol/fluticasone: Results From The Flame Study"], ["Donald Banerji", 2017, "Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus Salmeterol/fluticasone: Results From The Flame Study"], ["Sebastian Fucile", 2017, "Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus Salmeterol/fluticasone: Results From The Flame Study"], ["Jadwiga A Wedzicha", 2017, "Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus Salmeterol/fluticasone: Results From The Flame Study"], ["JM Fitzgerald", 2017, "Marijuana Smoking In The Middle-Aged And Elderly Population Is Associated With Exacerbation-Like Respiratory Events"], ["Jeremy D Road", 2017, "Marijuana Smoking In The Middle-Aged And Elderly Population Is Associated With Exacerbation-Like Respiratory Events"], ["Riyad Allehebi", 2017, "Association Between Changes In Asthma Control And Measures Of Lung Function"], ["Nicolas Roche", 2017, "Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial"], ["Felix JF Herth", 2017, "Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial"], ["Petter Olsson", 2017, "Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial"], ["J Lin", 2017, "Perception des m\u00e9decins de soins primaires et prise en charge de l\u2019asthme dans 6 pays: enqu\u00eate mondiale de l\u2019asthme aupr\u00e8s des m\u00e9decins \u00abGAPS\u00bb(The Global Asthma Physician Survey)"], ["T Greulich", 2017, "Perception des m\u00e9decins de soins primaires et prise en charge de l\u2019asthme dans 6 pays: enqu\u00eate mondiale de l\u2019asthme aupr\u00e8s des m\u00e9decins \u00abGAPS\u00bb(The Global Asthma Physician Survey)"], ["C Raherison", 2017, "Perception des m\u00e9decins de soins primaires et prise en charge de l\u2019asthme dans 6 pays: enqu\u00eate mondiale de l\u2019asthme aupr\u00e8s des m\u00e9decins \u00abGAPS\u00bb(The Global Asthma Physician Survey)"], ["K Gaalswyk", 2017, "Perception des m\u00e9decins de soins primaires et prise en charge de l\u2019asthme dans 6 pays: enqu\u00eate mondiale de l\u2019asthme aupr\u00e8s des m\u00e9decins \u00abGAPS\u00bb(The Global Asthma Physician Survey)"], ["M Gibbs", 2017, "Perception des m\u00e9decins de soins primaires et prise en charge de l\u2019asthme dans 6 pays: enqu\u00eate mondiale de l\u2019asthme aupr\u00e8s des m\u00e9decins \u00abGAPS\u00bb(The Global Asthma Physician Survey)"], ["D Hinds", 2017, "Perception des m\u00e9decins de soins primaires et prise en charge de l\u2019asthme dans 6 pays: enqu\u00eate mondiale de l\u2019asthme aupr\u00e8s des m\u00e9decins \u00abGAPS\u00bb(The Global Asthma Physician Survey)"], ["D Kourtney", 2017, "Perception des m\u00e9decins de soins primaires et prise en charge de l\u2019asthme dans 6 pays: enqu\u00eate mondiale de l\u2019asthme aupr\u00e8s des m\u00e9decins \u00abGAPS\u00bb(The Global Asthma Physician Survey)"], ["P Piazza", 2017, "Perception des m\u00e9decins de soins primaires et prise en charge de l\u2019asthme dans 6 pays: enqu\u00eate mondiale de l\u2019asthme aupr\u00e8s des m\u00e9decins \u00abGAPS\u00bb(The Global Asthma Physician Survey)"], ["Helmut Teschler", 2017, "CORRELATION BETWEEN CHANGE IN LUNG DENSITY AND LUNG FUNCTION PARAMETERS IN TREATED ALPHA-1 PROTEASE INHIBITOR (A (1)-PI) DEFICIENCY"], ["Gerard McElvaney", 2017, "CORRELATION BETWEEN CHANGE IN LUNG DENSITY AND LUNG FUNCTION PARAMETERS IN TREATED ALPHA-1 PROTEASE INHIBITOR (A (1)-PI) DEFICIENCY"], ["N Gerard McElvaney", 2017, "LONG-TERM EFFICACY OF A (1)-PI THERAPY IN RAPID AND RAPID EXTENSION TRIALS"], ["Robert Sandhaus", 2017, "LONG-TERM EFFICACY OF A (1)-PI THERAPY IN RAPID AND RAPID EXTENSION TRIALS"], ["James Stocks", 2017, "LONG-TERM EFFICACY OF A (1)-PI THERAPY IN RAPID AND RAPID EXTENSION TRIALS"], ["Angel FowlerTaylor", 2017, "EFFECT OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) VS SALMETEROL/FLUTICASONE (SFC) ON MODERATE OR SEVERE COPD EXACERBATIONS AND LUNG FUNCTION BASED ON BASELINE BLOOD EOSINOPHIL \u2026"], ["Anupama Shrinivasan", 2017, "EFFECT OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) VS SALMETEROL/FLUTICASONE (SFC) ON MODERATE OR SEVERE COPD EXACERBATIONS AND LUNG FUNCTION BASED ON BASELINE BLOOD EOSINOPHIL \u2026"], ["C Thach", 2017, "Einmal t\u00e4glich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal t\u00e4glich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens \u2026"], ["A FowlerTaylor", 2017, "Einmal t\u00e4glich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal t\u00e4glich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens \u2026"], ["JA Wedzicha", 2017, "Einmal t\u00e4glich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal t\u00e4glich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens \u2026"], ["P Olsson", 2017, "Einmal t\u00e4glich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal t\u00e4glich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens \u2026"], ["A Shrinivasan", 2017, "Einmal t\u00e4glich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal t\u00e4glich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens \u2026"], ["T Ayers", 2017, "Einmal t\u00e4glich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal t\u00e4glich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens \u2026"], ["F Patalano", 2017, "Einmal t\u00e4glich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal t\u00e4glich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens \u2026"], ["C Vogelmeier", 2017, "Einmal t\u00e4glich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal t\u00e4glich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens \u2026"], ["R Fogel", 2017, "Einmal t\u00e4glich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal t\u00e4glich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens \u2026"], ["D Banerji", 2017, "Einmal t\u00e4glich Indacaterol/Glycopyrronium (IND/GLY) reduziert COPD Exazerbationen im Vergleich zu zweimal t\u00e4glich Salmeterol/Fluticason (SFC) in COPD Patienten mit mindestens \u2026"], ["Christine R Jenkins", 2017, "Improving the management of COPD in women"], ["James F Donohue", 2017, "Improving the management of COPD in women"], ["MeiLan K Han", 2017, "Improving the management of COPD in women"], ["Ioanna Tsiligianni", 2017, "Improving the management of COPD in women"], ["Kenneth Gaalswyk", 2017, "Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)"], ["Michael Gibbs", 2017, "Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)"], ["Peter Piazza", 2017, "Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)"], ["K Davis", 2017, "Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)"], ["Chantal Raherison", 2017, "Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)"], ["Timm Greulich", 2017, "Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)"], ["M Adachi", 2017, "Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)"], ["David Hinds", 2017, "Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)"], ["Jiangtao Lin", 2017, "Physician Perspectives on the Burden and Management of Asthma in Six Countries: The Global Asthma Physician Survey (GAPS)"], ["John S Floras", 2017, "Complexity of Sympathetic Nerve Traffic in Human Heart Failure: Seeking Inspiration"], ["Darana Yuen", 2017, "A randomized controlled trial to determine the effect of inhaled corticosteroid on intraocular pressure in open-angle glaucoma and ocular hypertension: the ICOUGH Study"], ["Edward B Moss", 2017, "A randomized controlled trial to determine the effect of inhaled corticosteroid on intraocular pressure in open-angle glaucoma and ocular hypertension: the ICOUGH Study"], ["Yvonne M Buys", 2017, "A randomized controlled trial to determine the effect of inhaled corticosteroid on intraocular pressure in open-angle glaucoma and ocular hypertension: the ICOUGH Study"], ["Stephanie A Low", 2017, "A randomized controlled trial to determine the effect of inhaled corticosteroid on intraocular pressure in open-angle glaucoma and ocular hypertension: the ICOUGH Study"], ["Graham E Trope", 2017, "A randomized controlled trial to determine the effect of inhaled corticosteroid on intraocular pressure in open-angle glaucoma and ocular hypertension: the ICOUGH Study"], ["Ya-ping Jin", 2017, "A randomized controlled trial to determine the effect of inhaled corticosteroid on intraocular pressure in open-angle glaucoma and ocular hypertension: the ICOUGH Study"], ["S Fucile", 2017, "C79 ADVANCING UNDERSTANDING OF OBSTRUCTIVE LUNG DISEASE: MEDICATIONS AND MECHANISMS OF DELIVERY: Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus \u2026"], ["A Fowler Taylor", 2017, "C79 ADVANCING UNDERSTANDING OF OBSTRUCTIVE LUNG DISEASE: MEDICATIONS AND MECHANISMS OF DELIVERY: Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus \u2026"], ["CF Vogelmeier", 2017, "C79 ADVANCING UNDERSTANDING OF OBSTRUCTIVE LUNG DISEASE: MEDICATIONS AND MECHANISMS OF DELIVERY: Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus \u2026"], ["A Yadao", 2017, "C79 ADVANCING UNDERSTANDING OF OBSTRUCTIVE LUNG DISEASE: MEDICATIONS AND MECHANISMS OF DELIVERY: Improvement In Sgrq Component Score With Indacaterol/glycopyrronium Versus \u2026"], ["R Allehebi", 2017, "C80-B MULTI-MODALITY ASSESSMENT OF COPD, ASTHMA, AND ASTHMA-COPD OVERLAP SYNDROME: Association Between Changes In Asthma Control And Measures Of Lung Function"], ["J Burdon", 2017, "D103 ALPHA 1-ANTITRYPSIN DEFICIENCY: 50 YEARS OF PROGRESS: The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of \u2026"], ["B Stoel", 2017, "D103 ALPHA 1-ANTITRYPSIN DEFICIENCY: 50 YEARS OF PROGRESS: The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of \u2026"], ["O Vit", 2017, "D103 ALPHA 1-ANTITRYPSIN DEFICIENCY: 50 YEARS OF PROGRESS: The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of \u2026"], ["M Fries", 2017, "D103 ALPHA 1-ANTITRYPSIN DEFICIENCY: 50 YEARS OF PROGRESS: The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of \u2026"], ["JM Edelman", 2017, "D103 ALPHA 1-ANTITRYPSIN DEFICIENCY: 50 YEARS OF PROGRESS: The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of \u2026"], ["D Reed", 2017, "D103 ALPHA 1-ANTITRYPSIN DEFICIENCY: 50 YEARS OF PROGRESS: The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of \u2026"], ["M Wencker", 2017, "D103 ALPHA 1-ANTITRYPSIN DEFICIENCY: 50 YEARS OF PROGRESS: The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of \u2026"], ["NG McElvaney", 2017, "D103 ALPHA 1-ANTITRYPSIN DEFICIENCY: 50 YEARS OF PROGRESS: The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of \u2026"], ["D Parr", 2017, "D103 ALPHA 1-ANTITRYPSIN DEFICIENCY: 50 YEARS OF PROGRESS: The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of \u2026"], ["N Seersholm", 2017, "D103 ALPHA 1-ANTITRYPSIN DEFICIENCY: 50 YEARS OF PROGRESS: The Effect Of Alpha1-Proteinase Inhibitor (a1-Pi) Therapy On Changes In Regional Lung Density: Post-Hoc Analysis Of \u2026"], ["Emily Seto", 2017, "Self-management and clinical decision support for patients with complex chronic conditions through the use of smartphone-based telemonitoring: randomized controlled trial protocol"], ["Alexander G Logan", 2017, "Self-management and clinical decision support for patients with complex chronic conditions through the use of smartphone-based telemonitoring: randomized controlled trial protocol"], ["Heather J Ross", 2017, "Self-management and clinical decision support for patients with complex chronic conditions through the use of smartphone-based telemonitoring: randomized controlled trial protocol"], ["Patrick Ware", 2017, "Self-management and clinical decision support for patients with complex chronic conditions through the use of smartphone-based telemonitoring: randomized controlled trial protocol"], ["Joseph A Cafazzo", 2017, "Self-management and clinical decision support for patients with complex chronic conditions through the use of smartphone-based telemonitoring: randomized controlled trial protocol"], ["Phillip Segal", 2017, "Self-management and clinical decision support for patients with complex chronic conditions through the use of smartphone-based telemonitoring: randomized controlled trial protocol"], ["N Roche", 2017, "Reply to Correspondence Letter Regarding\" Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial"], ["FJF Herth", 2017, "Reply to Correspondence Letter Regarding\" Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial"], ["Robert A Sandhaus", 2017, "The effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trials"], ["Jerome O Cantor", 2017, "The effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trials"], ["Shuren Ma", 2017, "The effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trials"], ["Yong Y Lin", 2017, "The effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trials"], ["Gerard M Turino", 2017, "The effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trials"], ["Jan Chlumsky", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["RAPID Extension Trial Group", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Peter AB Wark", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Mark Holmes", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Paul I Stoicescu", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Michael A Tortorici", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Joanna Chorostowska-Wynimko", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Allan Glanville", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Philip J Thompson", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Marek Sanak", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Alan Altraja", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Joachim H Ficker", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Riitta M\u00e4kitaro", 2017, "Long-term efficacy and safety of \u03b11 proteinase inhibitor treatment for emphysema caused by severe \u03b11 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)"], ["Jos\u00e9 Chatkin", 2016, "The relationship between omega-3 and smoking habit: a cross-sectional study"], ["N\u00f3ris Scaglia", 2016, "The relationship between omega-3 and smoking habit: a cross-sectional study"], ["Ivone Ferreira", 2016, "The relationship between omega-3 and smoking habit: a cross-sectional study"], ["Johane Allard", 2016, "The relationship between omega-3 and smoking habit: a cross-sectional study"], ["Peter Selby", 2016, "The relationship between omega-3 and smoking habit: a cross-sectional study"], ["Mario Wagner", 2016, "The relationship between omega-3 and smoking habit: a cross-sectional study"], ["M Larbig", 2016, "ONCE-DAILY INDACATEROL/GLYCOPYRRONIUM (IND/GLY) IS MORE EFFECTIVE THAN TWICE-DAILY SALMETEROL/FLUTICASONE (SFC) IN REDUCING EXACERBATIONS IN COPD PATIENTS AT A HIGH RISK OF \u2026"], ["Pei Zhi Li", 2016, "The COPD Assessment Test: can it discriminate across COPD subpopulations?"], ["Nisha Gupta", 2016, "The COPD Assessment Test: can it discriminate across COPD subpopulations?"], ["Julie Olsson", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Phillip Korenblat", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Kun Peng", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Pierluigi Paggiaro", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Petr Kopecky", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Akihito Yokoyama", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["John G Matthews", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Sarah Gray", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Saloumeh K Fischer", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Mark Eisner", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Eric D Bateman", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Wendy S Putnam", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Cecile TJ Holweg", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Nicola A Hanania", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Charles Asare", 2016, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials"], ["Claus Vogelmeier", 2016, "Effect of indacaterol/glycopyrronium versus salmeterol/fluticasone on hypothalamic pituitary-adrenal axis function in moderate-to-very severe COPD patients: Results from the \u2026"], ["Jadwiga Wedzicha", 2016, "Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study"], ["Sarah Whelan", 2016, "Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD \u2026"], ["Karyn Clerkin", 2016, "Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD \u2026"], ["Mark Fitzgerald", 2016, "Marijuana smoking: Health and socioeconomic impact in middle-aged and elderly adults"], ["James Hogg", 2016, "Marijuana smoking: Health and socioeconomic impact in middle-aged and elderly adults"], ["Wan Cheng Tan", 2016, "Marijuana smoking: Health and socioeconomic impact in middle-aged and elderly adults"], ["Norbert Ahlers", 2016, "Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the \u2026"], ["Nicola Hanania", 2016, "LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma"], ["Pier L Paggiaro", 2016, "LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma"], ["Noel Gerard McElvaney", 2016, "Increased proportion of slow decliners in patients with alpha-1 protease inhibitor (A1-PI) deficiency following treatment with A1-PI"], ["J Charles Victor", 2016, "Factors associated with undiagnosed and overdiagnosed COPD"], ["Wan Tan", 2016, "Factors associated with undiagnosed and overdiagnosed COPD"], ["Jiandong Su", 2016, "Factors associated with undiagnosed and overdiagnosed COPD"], ["Andrea S Gershon", 2016, "Factors associated with undiagnosed and overdiagnosed COPD"], ["Jeremiah Hwee", 2016, "Factors associated with undiagnosed and overdiagnosed COPD"], ["Matthew B Stanbrook", 2016, "Factors associated with undiagnosed and overdiagnosed COPD"], ["Dennis O'Donnell", 2016, "Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use. Data from the CanCOLD study"], ["Laura E Labont\u00e9", 2016, "Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use. Data from the CanCOLD study"], ["R Timothy Ayers", 2016, "Indacaterol\u2013glycopyrronium versus salmeterol\u2013fluticasone for COPD"], ["J\u00f8rgen Vestbo", 2016, "Indacaterol\u2013glycopyrronium versus salmeterol\u2013fluticasone for COPD"], ["Stephanie Korn", 2016, "Assessing biomarkers in a real-world severe asthma study (ARIETTA)"], ["Giorgio W Canonica", 2016, "Assessing biomarkers in a real-world severe asthma study (ARIETTA)"], ["Nicolas Martin", 2016, "Assessing biomarkers in a real-world severe asthma study (ARIETTA)"], ["C\u00e9sar Picado", 2016, "Assessing biomarkers in a real-world severe asthma study (ARIETTA)"], ["Ramon Aguiar Escobar", 2016, "Assessing biomarkers in a real-world severe asthma study (ARIETTA)"], ["Stephan Korom", 2016, "Assessing biomarkers in a real-world severe asthma study (ARIETTA)"], ["Andrew Menzies-Gow", 2016, "Assessing biomarkers in a real-world severe asthma study (ARIETTA)"], ["Michel Aubier", 2016, "Assessing biomarkers in a real-world severe asthma study (ARIETTA)"], ["Roland Buhl", 2016, "Assessing biomarkers in a real-world severe asthma study (ARIETTA)"], ["J M FitzGerald", 2016, "The Relative Contribution Of A Low Baseline Fev1 Versus Rapid Decline In Lung Function Over Time On Incident COPD"], ["Denis O\u2019Donnell", 2016, "A Population Based Study Of Sleep Disorders In Chronic Obstructive Pulmonary Disease: Sleep Quality And Acute Exacerbations Of COPD"], ["RJ Kimoff", 2016, "A Population Based Study Of Sleep Disorders In Chronic Obstructive Pulmonary Disease: Sleep Quality And Acute Exacerbations Of COPD"], ["James M Stocks", 2016, "The effect of alpha-1 proteinase inhibitor (a1-PI) therapy on changes in regional lung density: a post-hoc analysis of the RAPID trial"], ["Guneet Boparai", 2016, "Exhaled Nitric Oxide As An Indirect Measure Of Compliance In Asthma"], ["Tiyas Sen Dutt", 2016, "Exhaled Nitric Oxide As An Indirect Measure Of Compliance In Asthma"], ["Ronald Olivenstein", 2016, "A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["James G Martin", 2016, "A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["Ryan Nantel-Smith", 2016, "A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["Marc Miravitlles", 2016, "Efficacy Of Aclidinium/formoterol On Bronchodilation And Symptoms In Symptomatic And Asymptomatic Patients With COPD: Pooled Analysis Of Two Phase Iii Studies"], ["Ferran Chuecos", 2016, "Efficacy Of Aclidinium/formoterol On Bronchodilation And Symptoms In Symptomatic And Asymptomatic Patients With COPD: Pooled Analysis Of Two Phase Iii Studies"], ["Anna Ribera", 2016, "Efficacy Of Aclidinium/formoterol On Bronchodilation And Symptoms In Symptomatic And Asymptomatic Patients With COPD: Pooled Analysis Of Two Phase Iii Studies"], ["Tobias Welte", 2016, "Current thinking and new paradigm for COPD"], ["Helgo Magnussen", 2016, "Current thinking and new paradigm for COPD"], ["S Rennard", 2016, "Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use"], ["L Rekeda", 2016, "Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use"], ["ED Bateman", 2016, "Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use"], ["K Chapman", 2016, "Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use"], ["EG Gil", 2016, "Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use"], ["M Moya", 2016, "Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with COPD, stratified by ICS use"], ["M Aubier", 2016, "Die ARIETTA-Studie: Biomarker bei schwerem Asthma in einem Real-World-Setting"], ["GW Canonica", 2016, "Die ARIETTA-Studie: Biomarker bei schwerem Asthma in einem Real-World-Setting"], ["R Buhl", 2016, "Die ARIETTA-Studie: Biomarker bei schwerem Asthma in einem Real-World-Setting"], ["N Martin", 2016, "Die ARIETTA-Studie: Biomarker bei schwerem Asthma in einem Real-World-Setting"], ["NA Hanania", 2016, "Die ARIETTA-Studie: Biomarker bei schwerem Asthma in einem Real-World-Setting"], ["C Picado", 2016, "Die ARIETTA-Studie: Biomarker bei schwerem Asthma in einem Real-World-Setting"], ["R Aguiar Escobar", 2016, "Die ARIETTA-Studie: Biomarker bei schwerem Asthma in einem Real-World-Setting"], ["A Menzies-Gow", 2016, "Die ARIETTA-Studie: Biomarker bei schwerem Asthma in einem Real-World-Setting"], ["S Korn", 2016, "Die ARIETTA-Studie: Biomarker bei schwerem Asthma in einem Real-World-Setting"], ["S Korom", 2016, "Die ARIETTA-Studie: Biomarker bei schwerem Asthma in einem Real-World-Setting"], ["M Tortorici", 2016, "DOSE-RESPONSE AND EXPOSURE-RESPONSE MODELING OF ALPHA1-PROTEINASE INHIBITOR (A1-PI) IN PATIENTS WITH A1-PI DEFICIENCY BASED ON RAPID AND RAPID EXTENSION TRIALS.: PI-132"], ["J Edelman", 2016, "DOSE-RESPONSE AND EXPOSURE-RESPONSE MODELING OF ALPHA1-PROTEINASE INHIBITOR (A1-PI) IN PATIENTS WITH A1-PI DEFICIENCY BASED ON RAPID AND RAPID EXTENSION TRIALS.: PI-132"], ["E Piitulainen", 2016, "DOSE-RESPONSE AND EXPOSURE-RESPONSE MODELING OF ALPHA1-PROTEINASE INHIBITOR (A1-PI) IN PATIENTS WITH A1-PI DEFICIENCY BASED ON RAPID AND RAPID EXTENSION TRIALS.: PI-132"], ["J Rogers", 2016, "DOSE-RESPONSE AND EXPOSURE-RESPONSE MODELING OF ALPHA1-PROTEINASE INHIBITOR (A1-PI) IN PATIENTS WITH A1-PI DEFICIENCY BASED ON RAPID AND RAPID EXTENSION TRIALS.: PI-132"], ["J Stocks", 2016, "DOSE-RESPONSE AND EXPOSURE-RESPONSE MODELING OF ALPHA1-PROTEINASE INHIBITOR (A1-PI) IN PATIENTS WITH A1-PI DEFICIENCY BASED ON RAPID AND RAPID EXTENSION TRIALS.: PI-132"], ["N McElvaney", 2016, "DOSE-RESPONSE AND EXPOSURE-RESPONSE MODELING OF ALPHA1-PROTEINASE INHIBITOR (A1-PI) IN PATIENTS WITH A1-PI DEFICIENCY BASED ON RAPID AND RAPID EXTENSION TRIALS.: PI-132"], ["R Sandhaus", 2016, "DOSE-RESPONSE AND EXPOSURE-RESPONSE MODELING OF ALPHA1-PROTEINASE INHIBITOR (A1-PI) IN PATIENTS WITH A1-PI DEFICIENCY BASED ON RAPID AND RAPID EXTENSION TRIALS.: PI-132"], ["M Bexon", 2016, "DOSE-RESPONSE AND EXPOSURE-RESPONSE MODELING OF ALPHA1-PROTEINASE INHIBITOR (A1-PI) IN PATIENTS WITH A1-PI DEFICIENCY BASED ON RAPID AND RAPID EXTENSION TRIALS.: PI-132"], ["Giorgio Walter Canonica", 2016, "The Arietta Study: Exploring Severe Asthma Biomarkers in a Real-World Setting"], ["Ram\u00f3n A Escobar", 2016, "The Arietta Study: Exploring Severe Asthma Biomarkers in a Real-World Setting"], ["Cesar Picado", 2016, "The Arietta Study: Exploring Severe Asthma Biomarkers in a Real-World Setting"], ["M Miravitlles", 2016, "D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Efficacy Of Aclidinium/formoterol On Bronchodilation And Symptoms In Symptomatic And Asymptomatic Patients With COPD: Pooled \u2026"], ["E Garcia Gil", 2016, "D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Efficacy Of Aclidinium/formoterol On Bronchodilation And Symptoms In Symptomatic And Asymptomatic Patients With COPD: Pooled \u2026"], ["F Chuecos", 2016, "D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Efficacy Of Aclidinium/formoterol On Bronchodilation And Symptoms In Symptomatic And Asymptomatic Patients With COPD: Pooled \u2026"], ["A Ribera", 2016, "D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Efficacy Of Aclidinium/formoterol On Bronchodilation And Symptoms In Symptomatic And Asymptomatic Patients With COPD: Pooled \u2026"], ["R Olivenstein", 2016, "B105 COPD: EPIDEMIOLOGY AND GENETICS: A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["J Bourbeau", 2016, "B105 COPD: EPIDEMIOLOGY AND GENETICS: A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["WC Tan", 2016, "B105 COPD: EPIDEMIOLOGY AND GENETICS: A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["JG Martin", 2016, "B105 COPD: EPIDEMIOLOGY AND GENETICS: A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["R Cowie", 2016, "B105 COPD: EPIDEMIOLOGY AND GENETICS: A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["P Hernandez", 2016, "B105 COPD: EPIDEMIOLOGY AND GENETICS: A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["R Nantel-Smith", 2016, "B105 COPD: EPIDEMIOLOGY AND GENETICS: A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["D Marciniuk", 2016, "B105 COPD: EPIDEMIOLOGY AND GENETICS: A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["SD Aaron", 2016, "B105 COPD: EPIDEMIOLOGY AND GENETICS: A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["JM FitzGerald", 2016, "B105 COPD: EPIDEMIOLOGY AND GENETICS: A Population Based Assessment Of Asthma And The Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (acos): A Canadian Perspective"], ["JM Stocks", 2016, "A43 ALPHA-1-ANTITRYPSIN DEFICIENCY: The Relationship Between Changes In CT-Measured Lung Density And Lung Volume In Severe Alpha-1 Antitrypsin Deficiency: Post-Hoc Analysis Of \u2026"], ["RA Sandhaus", 2016, "A43 ALPHA-1-ANTITRYPSIN DEFICIENCY: The Relationship Between Changes In CT-Measured Lung Density And Lung Volume In Severe Alpha-1 Antitrypsin Deficiency: Post-Hoc Analysis Of \u2026"], ["JG Matthews", 2016, "A31 ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND: Lavolta I And Ii: Design And Baseline Characteristics Of Two Phase Iii, Randomized, Double-Blind, Placebo-Controlled Studies To \u2026"], ["P Kopecky", 2016, "A31 ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND: Lavolta I And Ii: Design And Baseline Characteristics Of Two Phase Iii, Randomized, Double-Blind, Placebo-Controlled Studies To \u2026"], ["P Korenblat", 2016, "A31 ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND: Lavolta I And Ii: Design And Baseline Characteristics Of Two Phase Iii, Randomized, Double-Blind, Placebo-Controlled Studies To \u2026"], ["CTJ Holweg", 2016, "A31 ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND: Lavolta I And Ii: Design And Baseline Characteristics Of Two Phase Iii, Randomized, Double-Blind, Placebo-Controlled Studies To \u2026"], ["M Eisner", 2016, "A31 ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND: Lavolta I And Ii: Design And Baseline Characteristics Of Two Phase Iii, Randomized, Double-Blind, Placebo-Controlled Studies To \u2026"], ["P Paggiaro", 2016, "A31 ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND: Lavolta I And Ii: Design And Baseline Characteristics Of Two Phase Iii, Randomized, Double-Blind, Placebo-Controlled Studies To \u2026"], ["S Gray", 2016, "A31 ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND: Lavolta I And Ii: Design And Baseline Characteristics Of Two Phase Iii, Randomized, Double-Blind, Placebo-Controlled Studies To \u2026"], ["A Yokoyama", 2016, "A31 ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND: Lavolta I And Ii: Design And Baseline Characteristics Of Two Phase Iii, Randomized, Double-Blind, Placebo-Controlled Studies To \u2026"], ["J Olsson", 2016, "A31 ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND: Lavolta I And Ii: Design And Baseline Characteristics Of Two Phase Iii, Randomized, Double-Blind, Placebo-Controlled Studies To \u2026"], ["D O'Donnell", 2016, "C78 NOT STRANGERS IN THE NIGHT: SLEEP AND THORACIC DISEASES: A Population Based Study Of Sleep Disorders In Chronic Obstructive Pulmonary Disease: Sleep Quality And Acute \u2026"], ["M Kaminska", 2016, "C78 NOT STRANGERS IN THE NIGHT: SLEEP AND THORACIC DISEASES: A Population Based Study Of Sleep Disorders In Chronic Obstructive Pulmonary Disease: Sleep Quality And Acute \u2026"], ["M Shorofsky", 2016, "C78 NOT STRANGERS IN THE NIGHT: SLEEP AND THORACIC DISEASES: A Population Based Study Of Sleep Disorders In Chronic Obstructive Pulmonary Disease: Sleep Quality And Acute \u2026"], ["H Coxson", 2016, "C78 NOT STRANGERS IN THE NIGHT: SLEEP AND THORACIC DISEASES: A Population Based Study Of Sleep Disorders In Chronic Obstructive Pulmonary Disease: Sleep Quality And Acute \u2026"], ["N Ayas", 2016, "C78 NOT STRANGERS IN THE NIGHT: SLEEP AND THORACIC DISEASES: A Population Based Study Of Sleep Disorders In Chronic Obstructive Pulmonary Disease: Sleep Quality And Acute \u2026"], ["C Hague", 2016, "B93 THINKING ABOUT LUNG HEALTH AND DEFINING EARLY COPD: The Relative Contribution Of A Low Baseline Fev1 Versus Rapid Decline In Lung Function Over Time On Incident COPD"], ["L Zheng", 2016, "B93 THINKING ABOUT LUNG HEALTH AND DEFINING EARLY COPD: The Relative Contribution Of A Low Baseline Fev1 Versus Rapid Decline In Lung Function Over Time On Incident COPD"], ["J Leipsic", 2016, "B93 THINKING ABOUT LUNG HEALTH AND DEFINING EARLY COPD: The Relative Contribution Of A Low Baseline Fev1 Versus Rapid Decline In Lung Function Over Time On Incident COPD"], ["JC Hogg", 2016, "B93 THINKING ABOUT LUNG HEALTH AND DEFINING EARLY COPD: The Relative Contribution Of A Low Baseline Fev1 Versus Rapid Decline In Lung Function Over Time On Incident COPD"], ["M Kirby", 2016, "B93 THINKING ABOUT LUNG HEALTH AND DEFINING EARLY COPD: The Relative Contribution Of A Low Baseline Fev1 Versus Rapid Decline In Lung Function Over Time On Incident COPD"], ["Paul Hernadez", 2016, "C48 COPD: IMAGING: Radiological Phenotypes Of Smoking And Non-Smoking COPD"], ["Harvey O Coxson", 2016, "Findings on thoracic computed tomography scans and respiratory outcomes in persons with and without chronic obstructive pulmonary disease: a population-based cohort study"], ["Cameron J Hague", 2016, "Findings on thoracic computed tomography scans and respiratory outcomes in persons with and without chronic obstructive pulmonary disease: a population-based cohort study"], ["CanCOLD Collaborative Research group", 2016, "Findings on thoracic computed tomography scans and respiratory outcomes in persons with and without chronic obstructive pulmonary disease: a population-based cohort study"], ["Rekha Raju", 2016, "Findings on thoracic computed tomography scans and respiratory outcomes in persons with and without chronic obstructive pulmonary disease: a population-based cohort study"], ["Ekkehard Beck", 2016, "Overall and cardiovascular safety of aclidinium bromide in patients with COPD: a pooled analysis of six phase III, placebo-controlled, randomized studies"], ["Daniel Alcaide", 2016, "Overall and cardiovascular safety of aclidinium bromide in patients with COPD: a pooled analysis of six phase III, placebo-controlled, randomized studies"], ["KENNETH CHAPMAN", 2015, "PHYSICIAN PERCEPTIONS AND TREATMENT OF ASTHMA IN FIVE COUNTRIES: THE GLOBAL ASTHMA PHYSICIAN SURVEY: Abstract ID\u2013397"], ["Rachael Disantostefano", 2015, "PHYSICIAN PERCEPTIONS AND TREATMENT OF ASTHMA IN FIVE COUNTRIES: THE GLOBAL ASTHMA PHYSICIAN SURVEY: Abstract ID\u2013397"], ["Mitsuru Adachi", 2015, "PHYSICIAN PERCEPTIONS AND TREATMENT OF ASTHMA IN FIVE COUNTRIES: THE GLOBAL ASTHMA PHYSICIAN SURVEY: Abstract ID\u2013397"], ["KOURTNEY DAVIS", 2015, "PHYSICIAN PERCEPTIONS AND TREATMENT OF ASTHMA IN FIVE COUNTRIES: THE GLOBAL ASTHMA PHYSICIAN SURVEY: Abstract ID\u2013397"], ["Anthony D D\u2019Urzo", 2015, "Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised \u2026"], ["Eduard Molins", 2015, "Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised \u2026"], ["Anne Leselbaum", 2015, "Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised \u2026"], ["Deborah Casey", 2015, "Lost in Communication: Discrepancies Between Physician and Patient Reports of Medication-Related Education and Adverse Events in COPD"], ["Katherine Arias", 2015, "Lost in Communication: Discrepancies Between Physician and Patient Reports of Medication-Related Education and Adverse Events in COPD"], ["Ken Chapman", 2015, "Lost in Communication: Discrepancies Between Physician and Patient Reports of Medication-Related Education and Adverse Events in COPD"], ["Renata Rea", 2015, "Lost in Communication: Discrepancies Between Physician and Patient Reports of Medication-Related Education and Adverse Events in COPD"], ["Paul Jones", 2015, "Lost in Communication: Discrepancies Between Physician and Patient Reports of Medication-Related Education and Adverse Events in COPD"], ["Kim Lavoie", 2015, "Lost in Communication: Discrepancies Between Physician and Patient Reports of Medication-Related Education and Adverse Events in COPD"], ["Joseph Cafazzo", 2015, "Development of a novel mobile application to support self-management in patients with chronic obstructive pulmonary disease (COPD)"], ["Yeung Melanie", 2015, "Development of a novel mobile application to support self-management in patients with chronic obstructive pulmonary disease (COPD)"], ["Jonathan Edelman", 2015, "Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID"], ["Michael Tortorici", 2015, "Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID"], ["Martin Bexon", 2015, "Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID"], ["Tanja Rosenberg", 2015, "Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID"], ["James A Rogers", 2015, "Assessment of A1-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency"], ["Zhenling Yao", 2015, "Assessment of A1-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency"], ["A Sonia Buist", 2015, "Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study"], ["CanCOLD Collaborative Research Group", 2015, "Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study"], ["Matthew Heffer", 2015, "Impact of pulmonary nontuberculous mycobacterial treatment on pulmonary function tests in patients with and without established obstructive lung disease"], ["Theodore K Marras", 2015, "Impact of pulmonary nontuberculous mycobacterial treatment on pulmonary function tests in patients with and without established obstructive lung disease"], ["Mauli Mehta", 2015, "Impact of pulmonary nontuberculous mycobacterial treatment on pulmonary function tests in patients with and without established obstructive lung disease"], ["Liping Huang", 2015, "Intravenous augmentation treatment and lung density in severe \u03b11 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial"], ["Jonathan GW Burdon", 2015, "Intravenous augmentation treatment and lung density in severe \u03b11 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial"], ["Berend C Stoel", 2015, "Intravenous augmentation treatment and lung density in severe \u03b11 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial"], ["RAPID Trial Study Group", 2015, "Intravenous augmentation treatment and lung density in severe \u03b11 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial"], ["Ana C Bradi", 2015, "Alpha-1 antitrypsin deficiency in Canada: regional disparities in diagnosis and management"], ["Deborah K Casey", 2015, "Alpha-1 antitrypsin deficiency in Canada: regional disparities in diagnosis and management"], ["J M Fitzgerald", 2015, "Characterization Of\" Potentially Over Diagnosed\" Chronic Obstructive Pulmonary Disease Showed Early Disease: Results From The CanCOLD Study"], ["Stephen I Rennard", 2015, "Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with moderate to severe COPD, stratified by inhaled corticosteroid use"], ["Hassan Lakkis", 2015, "Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with moderate to severe COPD, stratified by inhaled corticosteroid use"], ["Miguel Moya", 2015, "Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with moderate to severe COPD, stratified by inhaled corticosteroid use"], ["AS Buist", 2015, "Risk Factors Of Non-Reversible Airway Obstruction In Never Smokers: Results From The Can Cold Study: Impact Of Gender And Severity Of Airway Obstruction"], ["Xin Yan", 2015, "Effect Of A1-Pi Augmentation Therapy On Biomarkers Of Elastin Degradation: Analysis Of Samples From The Rapid Trial"], ["Jiangtao He", 2015, "Effect Of A1-Pi Augmentation Therapy On Biomarkers Of Elastin Degradation: Analysis Of Samples From The Rapid Trial"], ["P Wark", 2015, "EFFECT OF QVA149 ON LUNG FUNCTION IN THE SUBGROUP OF PATIENTS WITH A HISTORY OF EXACERBATIONS IN THE PREVIOUS YEAR AND BASELINE ICS USE FROM THE SHINE STUDY: TP 048"], ["H Chen", 2015, "EFFECT OF QVA149 ON LUNG FUNCTION IN THE SUBGROUP OF PATIENTS WITH A HISTORY OF EXACERBATIONS IN THE PREVIOUS YEAR AND BASELINE ICS USE FROM THE SHINE STUDY: TP 048"], ["E Bateman", 2015, "EFFECT OF QVA149 ON LUNG FUNCTION IN THE SUBGROUP OF PATIENTS WITH A HISTORY OF EXACERBATIONS IN THE PREVIOUS YEAR AND BASELINE ICS USE FROM THE SHINE STUDY: TP 048"], ["R FOGEL", 2015, "EFFECT OF QVA149 ON LUNG FUNCTION IN THE SUBGROUP OF PATIENTS WITH A HISTORY OF EXACERBATIONS IN THE PREVIOUS YEAR AND BASELINE ICS USE FROM THE SHINE STUDY: TP 048"], ["Carlos Cezar Fritscher", 2015, "The prevalence of asthma and atopy in schoolchildren from Porto Alegre, Brazil, has plateaued"], ["Leandro Genehr Fritscher", 2015, "The prevalence of asthma and atopy in schoolchildren from Porto Alegre, Brazil, has plateaued"], ["Camila Schuh", 2015, "The prevalence of asthma and atopy in schoolchildren from Porto Alegre, Brazil, has plateaued"], ["HO Coxson", 2015, "C46 HOW DO YOU DO IT? COPD DIAGNOSIS AND ASSESSMENT: Characterization Of\" potentially Over Diagnosed\" Chronic Obstructive Pulmonary Disease Showed Early Disease: Results From \u2026"], ["A Buist", 2015, "C46 HOW DO YOU DO IT? COPD DIAGNOSIS AND ASSESSMENT: The Effect Of Smoking On The Threshold Of Bronchodilator Response (bdr) In Health And In COPD-Results From The Canadian \u2026"], ["J Fitzgerald", 2015, "C46 HOW DO YOU DO IT? COPD DIAGNOSIS AND ASSESSMENT: The Effect Of Smoking On The Threshold Of Bronchodilator Response (bdr) In Health And In COPD-Results From The Canadian \u2026"], ["D Sin", 2015, "C46 HOW DO YOU DO IT? COPD DIAGNOSIS AND ASSESSMENT: The Effect Of Smoking On The Threshold Of Bronchodilator Response (bdr) In Health And In COPD-Results From The Canadian \u2026"], ["S Ma", 2015, "B95 GETTING BETTER: ADVANCES IN COPD THERAPIES: Effect Of A1-Pi Augmentation Therapy On Biomarkers Of Elastin Degradation: Analysis Of Samples From The Rapid Trial"], ["X Yan", 2015, "B95 GETTING BETTER: ADVANCES IN COPD THERAPIES: Effect Of A1-Pi Augmentation Therapy On Biomarkers Of Elastin Degradation: Analysis Of Samples From The Rapid Trial"], ["YY Lin", 2015, "B95 GETTING BETTER: ADVANCES IN COPD THERAPIES: Effect Of A1-Pi Augmentation Therapy On Biomarkers Of Elastin Degradation: Analysis Of Samples From The Rapid Trial"], ["J He", 2015, "B95 GETTING BETTER: ADVANCES IN COPD THERAPIES: Effect Of A1-Pi Augmentation Therapy On Biomarkers Of Elastin Degradation: Analysis Of Samples From The Rapid Trial"], ["GM Turino", 2015, "B95 GETTING BETTER: ADVANCES IN COPD THERAPIES: Effect Of A1-Pi Augmentation Therapy On Biomarkers Of Elastin Degradation: Analysis Of Samples From The Rapid Trial"], ["Alan Kaplan", 2015, "Delayed Health Care Seeking Behavior and the Morbidity of COPD Exacerbations in Canada FREE TO VIEW"], ["Hungta Chen", 2015, "QVA149 improves lung function, dyspnea, and health status independent of previously prescribed medications and COPD severity: A subgroup analysis from the SHINE and ILLUMINATE \u2026"], ["Hulin Hu", 2015, "QVA149 improves lung function, dyspnea, and health status independent of previously prescribed medications and COPD severity: A subgroup analysis from the SHINE and ILLUMINATE \u2026"], ["Edward M Kerwin", 2015, "Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data"], ["Robert DiGiovanni", 2015, "Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data"], ["Huilin Hu", 2015, "Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data"], ["Pankaj Goyal", 2015, "Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data"], ["Pablo Altman", 2015, "Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data"], ["Peter D\u2019Andrea", 2015, "Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data"]]}